Roche: FDA approves Tecentriq

(CercleFinance.com) - The Swiss pharma giant Roche announces that the US FDA has approved Tecentriq as a first-line monotherapy for certain people suffering from metastatic non-small cell lung cancer.


This approval follows the IMpower110 phase III study, which demonstrated that Tecentriq has shown a significant overall survival in people with high PD-L1 expression compared to chemotherapy.

"We are pleased to offer people with certain types of lung cancer a new chemotherapy-free option that can help prolong their lives and be administered on a flexible dosing schedule, including an option for once-a-month Tecentriq infusions," said Levi Garraway, Chief Medical Officer and Head of Global Product Development.

He Added, "Today marks the fifth approval of Tecentriq in lung cancer, as we remain committed to providing an effective and tailored treatment option for every person diagnosed with this disease."


Copyright (c) 2020 CercleFinance.com. All rights reserved.